Pluronic-Functionalized Silica-Lipid Hybrid Microparticles: Improving the Oral Delivery of Poorly Water-Soluble Weak Bases

Molecular Pharmaceutics

Volumn 12, Issue 12, 2015, Pages 4424-4433

  Rao, Shasha ^a   Richter, Katharina ^a,c   Nguyen, Tri Hung ^b   Boyd, Ben J ^b   Porter, Christopher J H ^b   Tan, Angel ^a,d   Prestidge, Clive A ^a  

^a UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

^b MONASH UNIVERSITY   (Australia)

^c UNIVERSITY OF ADELAIDE   (Australia)

^d UNIVERSITY OF TOKYO   (Japan)

Author keywords

drug precipitation; oral bioavailability improvement; Pluronic; poorly water soluble drug; silica lipid hybrid; weak bases

Indexed keywords

CINNARIZINE; LABRASOL; LIPID; POLOXAMER; SILICON DIOXIDE; DRUG CARRIER; NANOPARTICLE; WATER;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG SOLUBILITY; IN VITRO STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PH; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; RAT; SOLID STATE; SPRAGUE DAWLEY RAT; ANIMAL; BIOAVAILABILITY; CHEMISTRY; MEDICINAL CHEMISTRY; ORAL DRUG ADMINISTRATION; PROCEDURES; SOLUBILITY;

ADMINISTRATION, ORAL; ANIMALS; BIOLOGICAL AVAILABILITY; CHEMISTRY, PHARMACEUTICAL; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; LIPIDS; MALE; NANOPARTICLES; POLOXAMER; RATS; RATS, SPRAGUE-DAWLEY; SILICON DIOXIDE; SOLUBILITY; WATER;

EID: 84949058284     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/acs.molpharmaceut.5b00622     Document Type: Article

References (50)

1. Williams, H. D.; Trevaskis, N. L.; Charman, S. A.; Shanker, R. M.; Charman, W. N.; Pouton, C. W.; Porter, C. J. H. Strategies to address low drug solubility in discovery and development Pharmacol. Rev. 2013, 65 (1) 315-499 10.1124/pr.112.005660
2. Gabr, K. E. Effect of organic acids on the release patterns of weakly basic drugs from inert sustained-release matrix tablets Eur. J. Pharm. Biopharm. 1992, 38 (6) 199-202
3. Kohri, N.; Yamayoshi, Y.; Xin, H. E.; Iseki, K. E. N.; Sato, N.; Todo, S.; Miyazaki, K. Improving the oral bioavailability of albendazole in rabbits by the solid dispersion technique J. Pharm. Pharmacol. 1999, 51 (2) 159-164 10.1211/0022357991772277
4. Lindfors, L.; Skantze, P.; Skantze, U.; Rasmusson, M.; Zackrisson, A.; Olsson, U. Amorphous drug nanosuspensions. 1. inhibition of Ostwald Ripening Langmuir 2006, 22 (3) 906-910 10.1021/la0523661
5. Tran, T. T.; Tran, P. H.; Choi, H.; Han, H.; Lee, B. The roles of acidifiers in solid dispersions and physical mixtures Int. J. Pharm. 2010, 384 (1-2) 60-66 10.1016/j.ijpharm.2009.09.039
6. Guzmán, H. R.; Tawa, M.; Zhang, Z.; Ratanabanangkoon, P.; Shaw, P.; Gardner, C. R.; Chen, H.; Moreau, J.-P.; Almarsson, Ö.; Remenar, J. F. Combined use of crystalline salt forms and precipitation inhibitors to improve oral absorption of celecoxib from solid oral formulations J. Pharm. Sci. 2007, 96 (10) 2686-2702 10.1002/jps.20906
7. Alhalaweh, A.; Ali, H. R. H.; Velaga, S. P. Effects of polymer and surfactant on the dissolution and transformation profiles of cocrystals in aqueous media Cryst. Growth Des. 2014, 14 (2) 643-648 10.1021/cg4015256
8. Xu, S.; Dai, W.-G. Drug precipitation inhibitors in supersaturable formulations Int. J. Pharm. 2013, 453 (1) 36-43 10.1016/j.ijpharm.2013.05.013
9. Warren, D. B.; Benameur, H.; Porter, C. J. H.; Pouton, C. W. Using polymeric precipitation inhibitors to improve the absorption of poorly water-soluble drugs: A mechanistic basis for utility J. Drug Target. 2010, 18 (10) 704-731 10.3109/1061186X.2010.525652
10. Ueda, K.; Higashi, K.; Yamamoto, K.; Moribe, K. Inhibitory effect of Hydroxypropyl Methylcellulose Acetate Succinate on drug recrystallization from a supersaturated solution assessed using nuclear magnetic resonance measurements Mol. Pharmaceutics 2013, 10 (10) 3801-3811 10.1021/mp400278j
11. Gao, P.; Akrami, A.; Alvarez, F.; Hu, J.; Li, L.; Ma, C.; Surapaneni, S. Characterization and optimization of AMG 517 supersaturatable self-emulsifying drug delivery system (S-SEDDS) for improved oral absorption J. Pharm. Sci. 2009, 98 (2) 516-528 10.1002/jps.21451
12. Gao, P.; Guyton, M. E.; Huang, T.; Bauer, J. M.; Stefanski, K. J.; Lu, Q. Enhanced oral bioavailability of a poorly water soluble drug PNU-91325 by supersaturatable formulations Drug Dev. Ind. Pharm. 2004, 30 (2) 221-229 10.1081/DDC-120028718
13. Gao, P.; Morozowich, W. Development of supersaturatable self-emulsifying drug delivery system formulations for improving the oral absorption of poorly soluble drugs Expert Opin. Drug Delivery 2006, 3 (1) 97-110 10.1517/17425247.3.1.97
14. Gao, P.; Rush, B. D.; Pfund, W. P.; Huang, T.; Bauer, J. M.; Morozowich, W.; Kuo, M.-S.; Hageman, M. J. Development of a supersaturable SEDDS (S-SEDDS) formulation of paclitaxel with improved oral bioavailability J. Pharm. Sci. 2003, 92 (12) 2386-2398 10.1002/jps.10511
15. Song, W.; Park, J.; Yeom, D.; Ahn, B.; Lee, K.; Lee, S.; Woo, H.; Choi, Y. Enhanced dissolution of celecoxib by supersaturating self-emulsifying drug delivery system (S-SEDDS) formulation Arch. Pharmacal Res. 2013, 36 (1) 69-78 10.1007/s12272-013-0011-z
16. Stillhart, C.; Dürr, D.; Kuentz, M. Toward an improved understanding of the precipitation behavior of weakly basic drugs from oral lipid-based formulations J. Pharm. Sci. 2014, 103 (4) 1194-1203 10.1002/jps.23892
17. Williams, H.; Trevaskis, N.; Yeap, Y.; Anby, M.; Pouton, C.; Porter, C. H. Lipid-based formulations and drug supersaturation: harnessing the unique benefits of the lipid digestion/absorption pathway Pharm. Res. 2013, 30 (12) 2976-2992 10.1007/s11095-013-1126-0
18. Anby, M. U.; Williams, H. D.; McIntosh, M.; Benameur, H.; Edwards, G. A.; Pouton, C. W.; Porter, C. J. H. Lipid digestion as a trigger for supersaturation: evaluation of the impact of supersaturation stabilization on the in vitro and in vivo performance of self-emulsifying drug delivery systems Mol. Pharmaceutics 2012, 9 (7) 2063-2079 10.1021/mp300164u
19. Vandecruys, R.; Peeters, J.; Verreck, G.; Brewster, M. E. Use of a screening method to determine excipients which optimize the extent and stability of supersaturated drug solutions and application of this system to solid formulation design Int. J. Pharm. 2007, 342 (1-2) 168-175 10.1016/j.ijpharm.2007.05.006
20. Tan, A.; Rao, S.; Prestidge, C. Transforming lipid-based oral drug delivery systems into solid dosage forms: an overview of solid carriers, physicochemical properties, and biopharmaceutical performance Pharm. Res. 2013, 30 (12) 2993-3017 10.1007/s11095-013-1107-3
21. Tan, A.; Eskandar, N.; Rao, S.; Prestidge, C. First in man bioavailability and tolerability studies of a silica-lipid hybrid (Lipoceramic) formulation: a Phase I study with ibuprofen Drug Delivery Transl. Res. 2014, 4 (3) 212-221 10.1007/s13346-013-0172-9
22. Rao, S.; Tan, A.; Boyd, B. J.; Prestidge, C. A. Synergistic role of self-emulsifying lipids and nanostructured porous silica particles in optimizing the oral delivery of lovastatin Nanomedicine 2014, 9 (18) 2745-2759 10.2217/nnm.14.37
23. Tan, A.; Prestidge, C. Nanostructured silica-lipid hybrid microparticles: a supersaturating carrier for water- and lipid-resistant compounds Chem. Lett. 2012, 41 (10) 1334-1336 10.1246/cl.2012.1334
24. Nguyen, T.-H.; Tan, A.; Santos, L.; Ngo, D.; Edwards, G. A.; Porter, C. J. H.; Prestidge, C. A.; Boyd, B. J. Silica-lipid hybrid (SLH) formulations enhance the oral bioavailability and efficacy of celecoxib: An in vivo evaluation J. Controlled Release 2013, 167 (1) 85-91 10.1016/j.jconrel.2013.01.012
25. Lim, L. H.; Tan, A.; Simovic, S.; Prestidge, C. A. Silica-lipid hybrid microcapsules: Influence of lipid and emulsifier type on in vitro performance Int. J. Pharm. 2011, 409 (1-2) 297-306 10.1016/j.ijpharm.2011.02.038
26. Tan, A.; Simovic, S.; Davey, A. K.; Rades, T.; Prestidge, C. A. Silica-lipid hybrid (SLH) microcapsules: a novel oral delivery system for poorly soluble drugs J. Controlled Release 2009, 134 (1) 62-70 10.1016/j.jconrel.2008.10.014
27. Dai, W. G.; Dong, L. C.; Li, S.; Deng, Z. Y. Combination of Pluronic/Vitamin E TPGS as a potential inhibitor of drug precipitation Int. J. Pharm. 2008, 355 (1-2) 31-37 10.1016/j.ijpharm.2007.12.015
28. Li, S.; Pollock-Dove, C.; Dong, L. C.; Chen, J.; Creasey, A. A.; Dai, W. G. Enhanced bioavailability of a poorly water-soluble weakly basic compound using a combination approach of solubilization agents and precipitation inhibitors: a case study Mol. Pharmaceutics 2012, 9 (5) 1100-1108 10.1021/mp200352q
29. Zhu, Q. L.; Guo, T.; Xia, D. N.; Li, X. Y.; Zhu, C. L.; Li, H. Y.; Ouyang, D. F.; Zhang, J. W.; Gan, Y. Pluronic F127-modified liposome-containing tacrolimus-cyclodextrin inclusion complexes: improved solubility, cellular uptake and intestinal penetration J. Pharm. Pharmacol. 2013, 65 (8) 1107-1117 10.1111/jphp.12074
30. Alinaghi, A.; Tan, A.; Rao, S.; Prestidge, C. A. Impact of solidification on the performance of lipid-based colloidal carriers: oil-based versus self-emulsifying systems Curr. Drug Delivery 2015, 12 (1) 16-25 10.2174/1567201811666140716122644
31. Sek, L.; Porter, C. J. H.; Kaukonen, A. M.; Charman, W. N. Evaluation of the in-vitro digestion profiles of long and medium chain glycerides and the phase behaviour of their lipolytic products J. Pharm. Pharmacol. 2002, 54 (1) 29-41 10.1211/0022357021771896
32. Sek, L.; Porter, C. J. H.; Charman, W. N. Characterisation and quantification of medium chain and long chain triglycerides and their in vitro digestion products, by HPTLC coupled with in situ densitometric analysis J. Pharm. Biomed. Anal. 2001, 25 (3-4) 651-661 10.1016/S0731-7085(00)00528-8
33. Batrakova, E. V.; Kabanov, A. V. Pluronic block copolymers: evolution of drug delivery concept from inert nanocarriers to biological response modifiers J. Controlled Release 2008, 130 (2) 98-106 10.1016/j.jconrel.2008.04.013
34. Adams, M. L.; Lavasanifar, A.; Kwon, G. S. Amphiphilic block copolymers for drug delivery J. Pharm. Sci. 2003, 92 (7) 1343-1355 10.1002/jps.10397
35. Creasey, A. A.; Dong, L. C.; Dai, W. G. Inhibiting the precipitation of poorly water-soluble drugs from Labrasol formulations. Pharm. Technol. 2011, 35, (6).
36. FDA. Inactive Ingredient Search for Approved Drug Products; U.S. Food and Drug Administration: http://www.fda.gov/Drugs/InformationOnDrugs/default.htm, 2013.
37. Simovic, S.; Heard, P.; Hui, H.; Song, Y.; Peddie, F.; Davey, A. K.; Lewis, A.; Rades, T.; Prestidge, C. A. Dry hybrid lipid-silica microcapsules engineered from submicron lipid droplets and nanoparticles as a novel delivery system for poorly soluble drugs Mol. Pharmaceutics 2009, 6 (3) 861-872 10.1021/mp900063t
38. Tan, A.; Martin, A.; Nguyen, T.-H.; Boyd, B. J.; Prestidge, C. A. Hybrid nanomaterials that mimic the food effect: controlling enzymatic digestion for enhanced oral drug absorption Angew. Chem., Int. Ed. 2012, 51 (22) 5475-5479 10.1002/anie.201200409
39. Binks, B. P.; Desforges, A.; Duff, D. G. Synergistic stabilization of emulsions by a mixture of surface-active nanoparticles and surfactant Langmuir 2007, 23 (3) 1098-1106 10.1021/la062510y
40. Van Speybroeck, M.; Williams, H. D.; Nguyen, T.-H.; Anby, M. U.; Porter, C. J. H.; Augustijns, P. Incomplete desorption of liquid excipients reduces the in vitro and in vivo performance of self-emulsifying drug delivery systems solidified by adsorption onto an inorganic mesoporous carrier Mol. Pharmaceutics 2012, 9 (9) 2750-2760 10.1021/mp300298z
41. Nguyen, T.-H.; Hanley, T.; Porter, C. J. H.; Larson, I.; Boyd, B. J. Phytantriol and glyceryl monooleate cubic liquid crystalline phases as sustained-release oral drug delivery systems for poorly water-soluble drugs II. In-vivo evaluation J. Pharm. Pharmacol. 2010, 62 (7) 856-865 10.1211/jpp.62.07.0006
42. Lee, K. W. Y.; Porter, C. J. H.; Boyd, B. J. The effect of administered dose of lipid-based formulations on the In Vitro and In Vivo performance of cinnarizine as a model poorly water-soluble drug J. Pharm. Sci. 2013, 102 (2) 565-578 10.1002/jps.23384
43. Tan, A.; Simovic, S.; Davey, A. K.; Rades, T.; Boyd, B. J.; Prestidge, C. A. Silica nanoparticles to control the lipase-mediated digestion of lipid-based oral delivery systems Mol. Pharmaceutics 2010, 7 (2) 522-532 10.1021/mp9002442
44. Lawrence, M. J. Surfactant systems: their use in drug delivery Chem. Soc. Rev. 1994, 23 (6) 417-424 10.1039/cs9942300417
45. Malmsten, M.; Lindman, B. Self-assembly in aqueous block copolymer solutions Macromolecules 1992, 25 (20) 5440-5445 10.1021/ma00046a049
46. Wulff-Pérez, M.; Gálvez-Ruíz, M. J.; de Vicente, J.; Martín-Rodríguez, A. Delaying lipid digestion through steric surfactant Pluronic F68: A novel in vitro approach Food Res. Int. 2010, 43 (6) 1629-1633 10.1016/j.foodres.2010.05.006
47. Feeney, O. M.; Williams, H. D.; Pouton, C. W.; Porter, C. J. H. 'Stealth' lipid-based formulations: Poly(ethylene glycol)-mediated digestion inhibition improves oral bioavailability of a model poorly water soluble drug J. Controlled Release 2014, 192 (0) 219-227 10.1016/j.jconrel.2014.07.037
48. Yeap, Y.; Trevaskis, N.; Porter, C. H. Lipid absorption triggers drug supersaturation at the intestinal unstirred water layer and promotes drug absorption from mixed micelles Pharm. Res. 2013, 30 (12) 3045-3058 10.1007/s11095-013-1104-6
49. Yeap, Y. Y.; Trevaskis, N. L.; Porter, C. J. H. The potential for drug supersaturation during intestinal processing of lipid-based formulations may be enhanced for basic drugs Mol. Pharmaceutics 2013, 10 (7) 2601-2615 10.1021/mp400035z
50. Yeap, Y. Y.; Trevaskis, N. L.; Quach, T.; Tso, P.; Charman, W. N.; Porter, C. J. H. Intestinal bile secretion promotes drug absorption from lipid colloidal phases via induction of supersaturation Mol. Pharmaceutics 2013, 10 (5) 1874-1889 10.1021/mp3006566